Q999--Nitric Oxide/Inotherapy
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System (VAGLAHS) has awarded a $71,960.00 contract to INO Therapeutics LLC for nitric oxide-based inhalation therapy. This sole-source award covers the proprietary INOtherapy System, INOmax DSIR® Plus delivery system, and INOmax® (nitric oxide) for inhalation, along with comprehensive support services.
Scope of Work
The awarded contract provides nitric oxide-based inhalation therapy for patient care, specifically to treat patients with acute respiratory distress syndrome (ARDS) and acute pulmonary hypertension. The scope includes the INOtherapy System, INOmax DSIR® Plus delivery system, INOmax® (nitric oxide) for inhalation, and accompanying services and products. These services encompass training, support, maintenance, and reliable pick-up and delivery, which are crucial for uninterrupted and effective patient care.
Contract & Timeline
- Awardee: INO Therapeutics LLC (UEI: XXQHL619FUN6)
- Award Amount: $71,960.00
- Award Date: February 26, 2026
- Set-Aside: None specified (sole-source justification)
- Product/Service Code: Q999 (Other Medical Services)
- Place of Performance: Department of Veterans Affairs, Tucson, Arizona
Evaluation
The contract was awarded on a sole-source basis. The justification states that INO Therapeutics LLC is the manufacturer and sole provider of the current INOtherapy System, INOmax DSIR® Plus delivery system, and INOmax® (nitric oxide) for inhalation, as well as accompanying services and products in the United States. It was determined that no other contractor could provide a system with the same state-of-the-art capabilities, proprietary technology, and extensive support.
Additional Notes
This award highlights the VA's reliance on INO Therapeutics LLC's proprietary technology for critical patient care. Future procurements for this specific therapy may also be sole-sourced or require unique capabilities only available from this provider.